ALK and neuroblastoma: Drug interactions between TNO155 and ceritinib were assessed using the EOB model (38), and EOB scores > 0 (indicating synergy for this methodology) were exclusively observed for neuroblastoma cell lines harboring ALK mutations (Fig. 2B).